Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Multicenter, Open-Label, Single Arm Study of the Safety and Tolerability of Pirfenidone (Esbriet®) in Combination With Nintedanib (Ofev®) in Patients With Idiopathic Pulmonary Fibrosis

NCT02598193 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02598193
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02598193 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Multicenter, Open-Label, Single Arm Study of the Safety and Tolerability of Pirfenidone (Esbriet®) in Combination With Nintedanib (Ofev®) in Patients With Idiopathic Pulmonary Fibrosis
Lead sponsor
Hoffmann-La Roche
Phase
Phase 4
Overall status
Completed
Start date
January 14, 2016
Completion date
May 16, 2017
Enrollment
89 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary fibrosis